Arcus Biosciences (RCUS) has drawn fresh attention after recent trading left the stock with a mixed return profile, including a 16.4% decline over the past month alongside a 43.9% gain over the past 3 ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and ...

Arcus Biosciences recently discontinued the Phase 3 STAR-221 and Phase 2 EDGE-Gastric studies of domvanalimab-based regimens in advanced gastric and esophageal cancers, after an interim analysis found ...

The Accra Regional Police Command has arrested Suleiman Danjumah, also known as Solomon Addai and Innocent, for unlawful possession of a firearm, narcotic substances and stolen items. His arrest on ...

The Accra Regional Police Command has arrested two suspects in separate but related intelligence-led operations over the unlawful possession of firearms, narcotic substances and suspected stolen items ...

Dec 12 (Reuters) - Arcus Biosciences (RCUS.N), opens new tab said on Friday it would stop a late-stage study testing its experimental cancer drug combination in patients with advanced stomach and ...

Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer. Arcus ...

Arcus Biosciences, Inc. (NYSE:RCUS) on Friday announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc. (NASDAQ: GILD), due to futility. • ...

A key late-stage trial of Arcus Biosciences and Gilead Sciences' anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several studies of the drug. The ...

The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futility Arcus is continuing to expand its development program for ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

The transaction value is based on the SEC Form 4 weighted average purchase price ($20.76) for the trades executed. How significant was this sale relative to Jaen Juan C.'s historical trading? This was ...